Over the last years, NK cells have gained significant attention in the field of cancer immunotherapy and many efforts are emerging for developing and engineering NK cell-based cancer immunotherapy. Obtaining a large quantity of NK cells requires a democratized cell isolation solution for both pre-clinical and clinical applications. The new MARS Bar system enables a new generation of large scale, magnetic CD56+ cell isolation technology for separation of Apheresis, Leukopaks, Whole Blood or Bone Marrow cell products.
